Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mallory

Showing results (141-150 of 158) with videos related to

Pageof 16
Sort By:
Scientific Reports|November 6, 2023
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variantsNita Patel, Jessica F Trost, Mimi Guebre-Xabier, et al.
Trials|March 9, 2024
Suicide prevention for substance using youth experiencing homelessness: study protocol for a randomized controlled trialNatasha Slesnick, Brittany Brakenhoff, Laura J Chavez, et al.
The Lancet. Infectious Diseases|January 17, 2025
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 studyKatia Alves, Karen Kotloff, R Scott McClelland, et al.
Vaccine|February 16, 2024
Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccineSeth Toback, Anthony M Marchese, Brandy Warren, et al.
Plos One|November 17, 2010
Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adultsBruce K Brown, Josephine Cox, Anita Gillis, et al.
Vaccine|June 4, 2023
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
Astrobiology|November 27, 2002
Cave biosignature suites: microbes, minerals, and MarsP J Boston, M N Spilde, D E Northup, et al.
The New England Journal of Medicine|February 3, 2023
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
The Journal of Infection|January 28, 2025
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trialChijioke Bennett, Gordon Chau, Erika Clayton, et al.
Expert Review of Vaccines|May 29, 2023
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccineEddie Underwood, Lisa M Dunkle, Shabir A Madhi, et al.
Pageof 16

Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Scientific Reports|November 6, 2023
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variantsNita Patel, Jessica F Trost, Mimi Guebre-Xabier, et al.
Trials|March 9, 2024
Suicide prevention for substance using youth experiencing homelessness: study protocol for a randomized controlled trialNatasha Slesnick, Brittany Brakenhoff, Laura J Chavez, et al.
The Lancet. Infectious Diseases|January 17, 2025
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 studyKatia Alves, Karen Kotloff, R Scott McClelland, et al.
Vaccine|February 16, 2024
Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccineSeth Toback, Anthony M Marchese, Brandy Warren, et al.
Plos One|November 17, 2010
Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adultsBruce K Brown, Josephine Cox, Anita Gillis, et al.
Vaccine|June 4, 2023
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
Astrobiology|November 27, 2002
Cave biosignature suites: microbes, minerals, and MarsP J Boston, M N Spilde, D E Northup, et al.
The New England Journal of Medicine|February 3, 2023
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
The Journal of Infection|January 28, 2025
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trialChijioke Bennett, Gordon Chau, Erika Clayton, et al.
Expert Review of Vaccines|May 29, 2023
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccineEddie Underwood, Lisa M Dunkle, Shabir A Madhi, et al.
Pageof 16